Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
The Ras Gene02:38

The Ras Gene

7.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.0K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metal Hydrogen-Bonded Organic Framework Constructed by an Aggregation-Caused-Quenching Fluorophore, but Achieving "Turn-On" Sensing Capacity.

Inorganic chemistry·2026
Same author

Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026
Same author

Extracellular vesicles in the tumor microenvironment: Diverse origins, multifaceted functions, and emerging therapeutic opportunities.

Translational research : the journal of laboratory and clinical medicine·2026
Same author

Molecular Basis for the Divergent Inhibition of α-Amylase and α-Glucosidase by Phenolic Acids: The Critical Role of Hydroxyl Substitution.

Foods (Basel, Switzerland)·2026
Same author

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.

Cancer letters·2026
Same author

Germline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors.

JCO precision oncology·2026

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.8K

The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.

Lixin Wan1,2, Ming Chen3, Juxiang Cao4

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. wwei2@bidmc.harvard.edu lixin.wan@moffitt.org caojuxi@gmail.com rutaocui@bu.edu ppandolf@bidmc.harvard.edu.

Cancer Discovery
|February 9, 2017
PubMed
Summary

FZR1 protein inhibits BRAF oncogenic activity through proteolysis and dimer disruption. Aberrant signaling involving ERK and CDK4 kinases promotes melanoma by suppressing FZR1, suggesting therapeutic targeting of these pathways.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.8K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • BRAF oncogene drives tumorigenesis via the RAS/RAF/MEK/ERK pathway.
  • Upstream regulators of BRAF activity and stability were previously undefined.

Purpose of the Study:

  • To elucidate the upstream pathways governing BRAF kinase activity and protein stability.
  • To define the role of FZR1 in regulating BRAF function in both normal and cancer cells.

Main Methods:

  • Investigated FZR1's interaction with BRAF in primary and cancer cells.
  • Utilized genetic manipulation (FZR1 depletion, Pten loss) and pharmacological inhibitors (CDK4, BRAF/MEK inhibitors).
  • Examined signaling pathways including ERK, AKT, and cyclin D1/CDK4.

Main Results:

  • FZR1 targets BRAF for degradation in primary cells and disrupts BRAF dimerization in cancer cells.
  • ERK and cyclin D1/CDK4 phosphorylate FZR1, inhibiting its activity and promoting melanomagenesis.
  • CDK4 and BRAF/MEK inhibitors restore FZR1 ligase activity.
  • FZR1 loss cooperates with AKT hyperactivation or Pten loss, leading to coactivation of BRAF/ERK and AKT signaling.

Conclusions:

  • A reciprocal suppression mechanism exists between FZR1 and BRAF in tumorigenesis.
  • Dysregulation of the FZR1-BRAF axis, driven by ERK and CDK4, contributes to BRAF hyperactivation in cancers.
  • Targeting cyclin D1/CDK4, alone or with BRAF/MEK inhibitors, shows potential as an anti-melanoma therapy.